NCT04744636已完成1 期
Target Involvement and Exploratory Biomarkers Investigations in Healthy Volunteers and in Patients With Type 2 Diabetes Mellitus
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Guanylate triphosphate cyclohydrolase (GTP-CH) investigations
研究概览
简要总结
The purpose of this study is to evaluate the vascular function and biomarkers in healthy volunteers and type 2 diabetic patients.
详细描述
The present interventional study will be performed in 3 groups of healthy volunteers of different ages and in type 2 diabetic patients without an investigational medicinal product administrated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy volunteers:
- •Age [18 -30], [50-59] and [60-70] years
- •Male and female healthy volunteers, except with skin types 5 and 6
- •Body weight ≥ 50 kg and BMI between [18.0 -28.0] kg/m^2 inclusive
- •Non or ex-smokers (defined as someone who completely stopped smoking for at least 1 month before the beginning of this study)
- •No clinically relevant findings in the medical history and physical examination, especially with regards to cardiovascular system, lung, liver and renal function
- •Normal blood and urine laboratory tests
- •Patients with type 2 diabetes (T2D) mellitus:
- •Male and female patients, except with skin types 5 and 6
- •Age [50 - 70] years
- •BMI ≤35 kg/m2
- •T2D patients (according to American Diabetes Association (ADA) criteria i.e. HbA1c > 6.5% or fasting plasma glucose > 126 mg/dL (7.00 mmol/L) or 2-hour glucose ≥ 200mg/dL (11.1mmol/L) after 75g oral glucose or glucose ≥200mg/dL (11.1mmol/L) at any time on two separate occasions (historic values and/or at selection)
- •Currently treated with Standards of Medical Care in T2D at stable doses for at least 3 months
- •Antihypertensive drugs allowed except beta-blockers and calcium antagonists
- •Non or ex-smokers (defined as someone who completely stopped smoking for at least 1 month before the beginning of this study)
- •Non inclusion Criteria:
- •Healthy volunteers:
- •Unlikely to co-operate in the study,
- •Participation in another interventional study, including last study drug intake, at the same time or within the 3 months preceding the selection visit; participation in non-interventional registries or epidemiological studies is allowed,
- •Deprived of his freedom by administrative or court order or under guardianship,
- •History or evidence of acute or chronic abuse of alcohol consumption of> 21 alcohol units per week for males and >14 units per week for females (1 alcohol unit = 100 mL of 12% wine; = 30 mL of 40% spirits; = 250 mL of 6% beer),
- •Positive alcohol breath test,
- •Positive cotinine test,
- •Known or suspected to be drug-dependent,
- •Positive result in urinary screening for drug abuse,
- •Pregnancy, breastfeeding or lactating,
- •Regular use of prescribed and non-prescribed drugs in the last 60 days before the day of investigations into the study except hormonal contraception (e.g. pill or hormonal intrauterine device (IUD) or hormonal implants or Nuva Ring) (if applicable),
- •Any drug intake of prescribed or non-prescribed drugs including over-counter drugs (except acetaminophen), herbal remedies or nutritional supplements such as multivitamins in the 2 weeks before the day of investigations unless the investigator deems this drug intake to be irrelevant for the purpose of this study and that can be temporarily suspended,
- •Intake of dipyridamol (contraindicated with adenosine infusion)
- •Known hypersensitivity to adenosine injection,
- •Any acute or chronic illness or clinically relevant findings (i.e. liver, kidney, cardiovascular diseases) in the selection visit examinations,
- •Patients with type II diabetes mellitus (T2D):
- •Unlikely to co-operate in the study,
- •Participation in another interventional study, including last study drug intake, at the same time or within the 3 months preceding the selection visit; participation in non-interventional registries or epidemiological studies is allowed,
- •Deprived of his freedom by administrative or court order or under guardianship,
- •Unwilling to allow his or her primary care practitioner to be notified of participation in the study and for information on a participant's medical history to be obtained from the general practitioner,
- •History or evidence of acute or chronic abuse of alcohol consumption of> 21 alcohol units per week for males and >14 units per week for females (1 alcohol unit = 100 mL of 12% wine; = 30 mL of 40% spirits; = 250 mL of 6% beer),
- •Positive alcohol breath test,
- •Positive cotinine test,
- •Known or suspected to be drug-dependent,
- •Positive result in urinary screening for drug abuse,
- •Pregnancy, breastfeeding or lactating,
- •Intake of dipyridamol (contraindicated with adenosine infusion)
- •Known hypersensitivity to adenosine injection,
- •Any acute or chronic illness or clinically relevant findings (i.e. liver,kidney, cardiovascular diseases) in the selection visit examinations.
排除标准
- 未提供
研究组 & 干预措施
Healthy volunteers aged of 18-30 years
Other
干预措施: Other (Drug)
Healthy volunteers aged of 50-59 years
Other
干预措施: Other (Drug)
Healthy volunteers aged of 60-70 years
Other
干预措施: Other (Drug)
Type 2 diabetic patients aged of 50-70 years
Other
干预措施: Other (Drug)
结局指标
主要结局
Guanylate triphosphate cyclohydrolase (GTP-CH) investigations
时间窗: Day 1
Genomic market (blood) DNA and/or RNA characteristics of genes such as GTP Cyclohydrolase 1 (GCH)
次要结局
- Adverse events(Through study completion, 3.5 weeks)
- Blood pressure supine(Day 1)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Identification of Biomarkers for Patients with Vascular AnomaliesVascular AnomalyGeneralized Lymphatic AnomalyKaposiform HemangioendotheliomaKaposiform LymphangiomatosisGorham-Stout DiseaseKlippel Trenaunay SyndromeCongenital Lipomatous Overgrowth, Vascular Malformations, and Epidermal NeviNCT03001180Children's Hospital Medical Center, Cincinnati1,000
招募中
不适用
Vascular Lab Resource (VLR) BiorepositoryCardiovascular DiseasesMetabolic DiseasePeripheral Artery DiseaseCarotid DiseaseAneurysmal DiseaseVenous DiseaseThrombosisLymphedemaLipedemaNon-Atherosclerotic Chronic Arterial Occlusive DiseaseFibromuscular DysplasiaArterial DissectionMay-Thurner SyndromeVasospasmThoracic Outlet SyndromeVasculitisNCT05628948The Cleveland Clinic500
Unknown
不适用
Novel Vascular Biomarkers Behaviour and Clinical Value in Heart Failure and CRTChronic Heart FailureNCT02541773University Hospitals Coventry and Warwickshire NHS Trust58
已完成
不适用
Evaluation of Effects of Exercise Training and ARB in DM PatientsVascular FunctionExercise TrainingNCT01053026National Taiwan University Hospital15
已完成
2 期
BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung CancerLung CancerNCT01263782M.D. Anderson Cancer Center64